Physician profile
Wanda Lynn Winkler
NPI 1912196643
$5,253.54
in general payments reported to CMS, 2019-2025
28 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what 91% of Family Health providers received nationally (typical 2025 total: $209).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $242 · 2022: $775 · 2023: $1,373 · 2024: $1,420 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,067 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,066.89 |
| Education | $169.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $652.59 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $621.96 | 2022-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals Lp | $540.44 | 2022-2025 | Farxiga, Lokelma |
| Calliditas Therapeutics US INC. | $500.58 | 2023-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $468.45 | 2022-2025 | Acthar |
| Vifor Pharma, INC. | $344.22 | 2022-2025 | Veltassa, Korsuva |
| Amgen INC. | $338.82 | 2021-2025 | Tavneos |
| Travere Therapeutics, INC. | $305.41 | 2023-2025 | |
| Ardelyx, INC. | $282.37 | 2024-2025 | Ibsrela |
| Ani Pharmaceuticals, INC. | $193.44 | 2024-2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $144.85 | 2023-2025 | Lupkynis |
| Akebia Therapeutics INC | $112.72 | 2025 | Vafseo |
| Shield Therapeutics INC | $109.10 | 2023-2025 | Accrufer |
| Novartis Pharmaceuticals Corporation | $107.36 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.40 | 2024-2025 | Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $80.93 | 2023-2025 | Benlysta, Shingrix |
| Opko Pharmaceuticals, LLC | $59.61 | 2025 | Rayaldee |
| Apellis Pharmaceuticals, INC. | $47.04 | 2025 | Empaveli |
| Lilly USA, LLC | $46.39 | 2023-2024 | Jardiance |
| Fresenius USA Marketing, INC. | $31.21 | 2025 | Velphoro |
| Alexion Pharmaceuticals, INC. | $28.99 | 2025 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $25.97 | 2025 | Onpattro |
| Kyowa Kirin, INC. | $25.65 | 2023 | |
| Xeris Pharmaceuticals, INC. | $23.31 | 2023 | Keveyis |
| Ultragenyx Pharmaceutical INC. | $21.99 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.46 | 2023 | |
| Horizon Therapeutics Plc | $18.02 | 2023 | Krystexxa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wanda Winkler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.